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Background:Patients with an atrial septum defect (ASD) tend to develop progressive pulmonary arterial hypertension (PAH). Recent studies 
showed that a secretory phospholipase A2 (sPLA2) inhibitor could rescue PAH by acting on ion channel activity. We aimed to survey the changes of 
sPLA2 and its association with PAH after the percutaneous closure device intervention on ASD patients.
methods and results: Forty-two ASD (88.1% female) patients, mean age of 40.7 ± 18.5 years, were compared with a sex-age- matched control 
group (n=40). The mean PA pressure of ASD patients was 35.1 ± 7.6 (16 to 81) mmHg. Compared with the control subjects, ASD patients had higher 
level of sPLA2 (274 ± 44 vs. 172 ± 13 ng/dl, p<0.01). The age, ASD size, and PA pressure were all positively correlated with sPLA2 level (all p<0.05); 
with PA pressure had the most significant correlation. ASD patients with PAH had higher sPLA2 than those without (298 ± 32 vs. 230 ± 22 ng/dl, 
p<0.02). After ASD occlude procedure, the level of sPLA2 decreased significantly among those with baseline PAH subgroup (Δ=-120 ± 22 ng/dl, 
p<0.01), but not without PAH subgroup (Δ=-43 ± 20 ng/dl, p=0.09). However, the sPLA2 levels were similar in both groups after procedure (p=0.42). 
Furthermore, the change of sPLA2 was also strongly associated with the decreased level of PAH after procedure (R=0.45, p=0.002).
conclusions: Our results support the findings that sPLA2 is crucial in PAH under ASD condition and has a both therapeutic and pathophysiologic 
role for further treatment strategy.
